Clinical Trials Logo

Clinical Trial Summary

There are many different views regarding ideal duration and type of thromboprophylaxis after hip or knee surgery. An important factor in Fast-track surgery is early mobilization, which in itself is thought to prevent clotting. The investigators hypothesize that there is no increase with regards to thrombosis in patients receiving fast-track surgery with early mobilization and chemical thrombosis prophylaxis only during hospitalization.


Clinical Trial Description

Major orthopaedic surgery is related to development of thrombosis. It is well known that pharmacological prophylaxis reduces the risk of thrombosis after surgery but there are still doubt about the best type of prophylaxis and duration of treatment. The American College of Chest Physicians recommend thromboprophylaxis with either Low molecular weight heparin, factor Xa-inhibitors or Vitamin-K-antagonists for up til 10 days after total knee replacement (TKR) and 35 days after total hip replacement(THR). However whether these recommendations are applicable in fast-track patients receiving early mobilisation is uncertain. Studies on fast-track patients receiving early mobilisation and thrombosis prophylaxis only during hospitalisation showed very small incidence of symptomatic thromboembolic events. Therefore we conduct a quality-cohort-study on all patients receiving fast-track TKR/THR with short-term anti-thrombotic treatment, in order to investigate frequency of symptomatical deep vein thrombosis, pulmonary embolus, acute myocardial infarction and stroke. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01557725
Study type Observational
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase
Start date February 2010
Completion date May 2013

See also
  Status Clinical Trial Phase
Recruiting NCT04115436 - Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation
Completed NCT04412304 - Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
Recruiting NCT06238115 - Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair Phase 2/Phase 3
Completed NCT01774357 - Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems
Recruiting NCT02342444 - Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD) Phase 4
Completed NCT02052544 - Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device N/A